Company Overview
Oragenics, Inc. operates as a development-stage company focused on the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases within the United States. The company is situated within the Healthcare sector and specifically functions in the Biotechnology industry, where it pursues the creation of novel therapeutic agents like ONP-002, a fully synthetic, non-naturally occurring neurosteroid intended for nasal administration. Regarding its scale, the company currently maintains a market capitalization of $2.30M and employs a workforce of 3 individuals, with reported annual revenue figures listed as N/A for the trailing twelve months. The market cap figure of $2.30M indicates that the company is in an early-stage growth phase with limited capitalization relative to established peers, while the absence of reported revenue suggests the business is still prioritizing clinical development and product formulation over commercial sales generation.
Financial Health
The financial statements for the trailing twelve months show revenue of N/A, a net income of $-9,842,487, and an EBITDA figure listed as N/A, revealing a significant gap between top-line activity and bottom-line profitability. This substantial negative net income of $-9,842,487 highlights a cost structure where expenses, likely driven by research and development expenditures and operational overhead, far exceed any current revenue streams generated by the company. The free cash flow stands at $-5,746,671, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating positive cash flow from current business activities. When analyzing the margins, the gross margin is recorded at 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, indicating that the company has not yet achieved a sustainable positive margin structure typical of mature pharmaceutical entities. The balance sheet comparison reveals that the company holds $8.40M in cash against $227,348 in debt, supported by a debt-to-equity ratio of 2.75, which suggests a highly leveraged capital structure relative to equity but provides a cash buffer against the reported debt load. Liquidity is assessed via a current ratio of 5.64, which indicates a robust ability to cover short-term obligations with short-term assets, despite the negative earnings. Return on Equity is reported at -243.9% and Return on Assets at -101.4%, metrics that reveal that management has not yet achieved profitability and that the company is currently generating negative returns on its invested capital base.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is recorded at -0.05, implying that expected earnings are currently negative and traditional valuation multiples based on earnings are not applicable at this stage. The price-to-book ratio is 0.27, which indicates that the market is valuing the company at a fraction of its book value, suggesting a deep discount relative to the net asset value or reflecting high risk associated with the development-stage nature of the biotechnology firm. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are listed as N/A, which suggests that analysts cannot apply these standard valuation methods due to the absence of reported sales or positive earnings to serve as a denominator. Historical price action shows a 52-week high of $9.60 and a 52-week low of $0.52, providing the range within which the stock has traded over the last year. The beta value is 1.11, which means the stock's price volatility is slightly higher than the broader market, reacting more aggressively to market movements than a standard benchmark asset.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company is not yet in a phase where historical growth rates can be calculated or are significant enough to report in standard financial filings. Because the company is a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders, instead retaining all capital to reinvest into research, development, and the expansion of its nasal delivery therapy pipeline. The overall growth and income profile for Oragenics, Inc. is characterized by a lack of current commercial growth metrics and a complete absence of dividend income, focusing entirely on the potential future value of its pipeline assets.